title: Identification of D1-like dopamine receptors on human blood platelets.
abstract: Dopamine is able to inhibit the epinephrine-induced aggregation of human blood platelets, but the mechanism of action has not been elucidated. In this study we report that membranes from human blood platelets possess high affinity, saturable and stereoselective binding sites for the D1 dopamine receptor antagonist (3H) SCH 23390. (3H) SCH 23390 appeared to label a single class of binding sites with a Bmax of 18.6 +/- 1.6 fmol/mg protein and a KD of 0.8 nM. The potencies of different dopaminergic antagonists and agonists in displacing (3H) SCH 23390 from blood platelet membranes were similar to those obtained for striatal membranes. Unlike the classically defined D1 receptors, e.g. those in striatum, the D1 receptor sites on platelets appeared not to be coupled to the adenylate cyclase system, hence the term "D1-like". The D1 agonist SKF 38393 was more potent than dopamine in inhibiting platelet aggregation induced by epinephrine, and the effects of dopamine and SKF 38393 were prevented by SCH 23390. These results suggest that the inhibitory action of dopamine on the epinephrine-induced platelet aggregation is mediated through these D1-like receptors.
authors.affiliation: Department of Neurology, Akademisch Ziekenhuis, Vrije Universiteit Brussel, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: De Keyser
authors.forename: M
authors.initials: M
authors.lastname: De Waele
authors.forename: A
authors.initials: A
authors.lastname: Convents
authors.forename: G
authors.initials: G
authors.lastname: Ebinger
authors.forename: G
authors.initials: G
authors.lastname: Vauquelin
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000262:Adenylyl Cyclases / Q000097:blood; D000527:Alprostadil / Q000494:pharmacology; D001552:Benzazepines / Q000097:blood / Q000494:pharmacology; D001667:Binding, Competitive; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood; D004298:Dopamine / Q000097:blood / Q000494:pharmacology; D018492:Dopamine Antagonists; D004837:Epinephrine / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000097:blood; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000378:metabolism*; D017447:Receptors, Dopamine D1; D011985:Receptors, Serotonin / Q000378:metabolism
chemical_list: D001552:Benzazepines; D018492:Dopamine Antagonists; D010975:Platelet Aggregation Inhibitors; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D011985:Receptors, Serotonin; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000242:Cyclic AMP; D019204:GTP-Binding Proteins; D000262:Adenylyl Cyclases; D000527:Alprostadil; D004298:Dopamine; D004837:Epinephrine